TENET i2c Competition at #inventures2022, (1st prize: $10,000)
Zymedyne would like to congratulate CEO Chris Bladen on winning the “Engineering solutions for human and animal health” TENET i2c Competition at #inventures2022, (1st prize: $10,000)
LIBI Podcast Supported by Rainforest Alberta
Peter Beaudoin Hosts Zymedyne CEO & Co-founder on the Leaders, Innovators & Big Ideas (LIBI) podcast. To listen, visit: https://www.podbean.com/ew/pb-b7h2f-11b0817
Zymedyne ACS Chemical Neuroscience Publication
Zymedyne is excited to report some of their groundbreaking research in the leading Journal ACS Chemical Neuroscience! Link to publication: https://pubs.acs.org/doi/10.1021/acschemneuro.1c00765?ref=pdf
Parex Innovation Fellowship
Zymedyne is pleased to announce that Co-founder Dr.Gerald Zamponi has received a “Parex Innovation Fellowship” from the University of Calgary for his outstanding work on T-type channels and pain research. This fellowship will help to provide funds for Zymedyne research and patenting costs associated with developing our novel pain therapeutics platform. Read more about it here: https://science.ucalgary.ca/research-innovation/innovation/parex-innovation-fellows/gerald-zamponi
Campus Alberta Neuroscience Grant
Zymedyne Therapeutics is pleased to announce that it has been awarded an Entrepreneurship Seed grant from Campus Alberta Neuroscience (CAN).